MET Amplification Leads to Gefitinib Resistance in Lung Cancer by Activating ERBB3 Signaling
MET and TP 53: How They Relate to ALK Lung Cancer — ALK POSITIVE
Immunotherapy in non-small cell lung cancer harbouring driver mutations - Cancer Treatment Reviews
Diagnosis and Discussion -- Case 1068
Targeting MET in Cancer: Obstacles and Potentials | Insight Medical Publishing
Sensitivity and Resistance of MET Exon 14 Mutations in Lung Cancer to Eight MET Tyrosine Kinase Inhibitors In Vitro - Journal of Thoracic Oncology
MET Signaling: Novel Targeted Inhibition and Its Clinical Development in Lung Cancer - Journal of Thoracic Oncology
MET Exon 14 Skipping Alterations in NSCLC: Current Understanding and Therapeutic Advances - touchONCOLOGY
MET Oncogene in Non-Small Cell Lung Cancer: Mechanism of MET Dysregula | OTT
References in Lung cancer: current therapies and new targeted treatments - The Lancet
The race to target MET exon 14 skipping alterations in non-small cell lung cancer: The Why, the How, the Who, the Unknown, and the Inevitable - Lung Cancer
Capmatinib in MET Exon 14–Mutated or MET-Amplified Non–Small-Cell Lung Cancer | NEJM
MET inhibitors for targeted therapy of EGFR TKI-resistant lung cancer | Journal of Hematology & Oncology | Full Text
Lung cancer with MET exon 14 skipping mutation | LCTT
Biomarkers in Lung Cancer: Integration with Radiogenomics Data | IntechOpen
Types of Lung Cancer | LUNGevity Foundation
Location of the MET mutation found in familial EGFR-mutant lung cancer.... | Download Scientific Diagram
Research Increasingly Points to the Role of Molecular Diversity in Metastatic Lung Cancer - The ASCO Post
Introduction - Targeting METex14 NSCLC - Text Module - MET Inhibition in NSCLC - Oncology - Clinical Care Options
Lung cancer - The Lancet
Targeting MET in Lung Cancer: Will Expectations Finally Be MET? - ScienceDirect
Mutational profiles in non-small cell lung cancer. (A) Oncogenic driver... | Download Scientific Diagram
Antitumor activity of crizotinib in lung cancers harboring a MET exon 14 alteration | Nature Medicine
The race to target MET exon 14 skipping alterations in non-small cell lung cancer: The Why, the How, the Who, the Unknown, and the Inevitable - ScienceDirect
